Young Investigator and Patient-Centered Clinical Research Awards

Funding Agency:
Bladder Cancer Advocacy Network

BCAN’s Young Investigator Awards support outstanding early-career scientists and clinical cancer researchers with a demonstrated commitment to improving the understanding and treatment of bladder cancer and/or upper tract urothelial cancer. Applicants may be working in basic, translational, clinical, epidemiologic, bioengineering sciences or any other field, but projects must be specific to bladder cancer and/or upper tract urothelial carcinoma, and the applicant’s research environment must be capable of supporting transformational bladder cancer research.

The Patient-Centered Clinical Research Young Investigator Award (PCC-YIA) supports early-career scientists and clinical cancer researchers investigating transformational patient-oriented clinical bladder cancer and/or upper tract urothelial cancer research (e.g. studies of shared decision making, access to care, quality of care, quality of life, health disparities, comparative effectiveness research, patient-centered outcomes research, and survivorship).

Deadline: Feb. 22, 2024

Agency Website

Eligibility Requirements

  • Applicant must be from a US or Canadian sponsoring academic, non-profit or governmental institution.
  • Applicant must be within 6 years of completion of a professional degree or clinical training and may not hold the title of Associate Professor or higher at the time of submission.
  • Prior BCAN Young Investigator Award winners are not eligible to apply for this award.
  • Applicants may not have other funding with significant scientific overlap.

Amount

$75,000

Amount Description

Project Period: 1 year

Total Funding: $75,000; Indirect costs are not allowable

Funding Type

Grant

Eligibility

Junior Faculty
Medical Fellow/Resident
Post Doctoral Fellows

Category

Engineering and Physical Sciences
Environmental & Life Sciences
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 22, 2024